The Contribution of Angiogenesis to the Process of Metastasis

Cancer Journal (United States)

Volumn 21, Issue 4, 2015, Pages 267-273

  Bielenberg, Diane R ^a   Zetter, Bruce R ^a  

^a BOSTON CHILDREN S HOSPITAL   (United States)

Author keywords

Angiogenesis; antiangiogenesis; cancer; EMT; endothelial cell; lymphangiogenesis; malignant; metastasis; tumor; vessel

Indexed keywords

ANGIOGENESIS INHIBITOR;

ANGIOGENESIS; ANTIANGIOGENIC THERAPY; DISTANT METASTASIS; HUMAN; LYMPH NODE METASTASIS; LYMPHANGIOGENESIS; MALIGNANT NEOPLASTIC DISEASE; METASTASIS; NONHUMAN; PRIORITY JOURNAL; REVIEW; TUMOR GROWTH; TUMOR MICROENVIRONMENT; EPITHELIAL MESENCHYMAL TRANSITION; NEOPLASMS; NEOVASCULARIZATION, PATHOLOGIC; VASCULARIZATION;

ANGIOGENESIS INHIBITORS; EPITHELIAL-MESENCHYMAL TRANSITION; HUMANS; LYMPHANGIOGENESIS; LYMPHATIC METASTASIS; NEOPLASM METASTASIS; NEOPLASMS; NEOVASCULARIZATION, PATHOLOGIC;

EID: 84938580435     PISSN: 15289117     EISSN: 1540336X     Source Type: Journal    
DOI: 10.1097/PPO.0000000000000138     Document Type: Review

References (81)

1. Tannock IF. The relation between cell proliferation and the vascular system in a transplantedmouse mammary tumour. Br J Cancer. 1968;22:258-273.
2. Folkman J. Tumor angiogenesis: therapeutic implications. N Engl J Med. 1971;285:1182-1186.
3. Shing Y, Folkman J, Sullivan R, et al. Heparin affinity: purification of a tumor-derived capillary endothelial cell growth factor. Science. 1984;223: 1296-1299.
4. KlagsbrunM,D'Amore PA. Regulators of angiogenesis. Annu Rev Physiol. 1991;53:217-239.
5. Folkman J. The role of angiogenesis in tumor growth. Semin Cancer Biol. 1992;3:65-71.
6. Iruela-Arispe ML, Dvorak HF. Angiogenesis: a dynamic balance of stimulators and inhibitors. Thromb Haemost. 1997;78:672-677.
7. Fidler IJ, Kumar R, Bielenberg DR, et al. Molecular determinants of angiogenesis in cancer metastasis. Cancer J Sci Am. 1998;4(suppl 1):S58-S66.
8. Nagy JA, Chang SH, Shih SC, et al. Heterogeneity of the tumor vasculature. Semin Thromb Hemost. 2010;36:321-331.
9. D'Amore PA. Capillary growth: a two-cell system. Semin Cancer Biol. 1992;3:49-56.
10. Hanahan D, Folkman J. Patterns and emerging mechanisms of the angiogenic switch during tumorigenesis. Cell. 1996;86:353-364.
11. Hanahan D,Weinberg RA. The hallmarks of cancer. Cell. 2000;100:57-70.
12. Hanahan D, Weinberg RA. Hallmarks of cancer: the next generation. Cell. 2011;144:646-674.
13. Folkman J. Is angiogenesis an organizing principle in biology and medicine? J Pediatr Surg. 2007;42:1-11.
14. Orimo A, Weinberg RA. Stromal fibroblasts in cancer: a novel tumorpromoting cell type. Cell Cycle. 2006;5:1597-1601.
15. Watnick RS. The role of the tumor microenvironment in regulating angiogenesis. Cold Spring Harb Perspect Med. 2012;2:A006676.
16. Orimo A, Gupta PB, Sgroi DC, et al. Stromal fibroblasts present in invasive human breast carcinomas promote tumor growth and angiogenesis through elevated SDF-1/CXCL12 secretion. Cell. 2005;121:335-348.
17. Deryugina EI, Quigley JP. Tumor angiogenesis: MMP-mediated induction of intravasation-and metastasis-sustaining neovasculature. Matrix Biol. 2015;44-46C:94-112.
18. Amin DN, Bielenberg DR, Lifshits E, et al. Targeting EGFR activity in blood vessels is sufficient to inhibit tumor growth and is accompanied by an increase in VEGFR-2 dependence in tumor endothelial cells. Microvasc Res. 2008;76:15-22.
19. Amin DN, Hida K, Bielenberg DR, et al. Tumor endothelial cells express epidermal growth factor receptor (EGFR) but not ErbB3 and are responsive to EGF and to EGFR kinase inhibitors. Cancer Res. 2006;66:2173-2180.
20. Récamier JCA. Recherches sur le Traitment du Cancer. Paris, France: Gabon; 1829.
21. Talmadge JE, Fidler IJ. AACR centennial series: the biology of cancer metastasis: historical perspective. Cancer Res. 2010;70:5649-5669.
22. Fidler IJ. Metastasis: quantitative analysis of distribution and fate of tumor embolilabeled with 125I-5-iodo-2-deoxyuridine. J Natl Cancer Inst. 1970; 45:773-782.
23. Butler TP, Gullino PM. Quantitation of cell shedding into efferent blood of mammary adenocarcinoma. Cancer Res. 1975;35:512-516.
24. Fidler IJ. The pathogenesis of cancer metastasis: the 'seed and soil' hypothesis revisited. Nat Rev Cancer. 2003;3:453-458.
25. Valastyan S, Weinberg RA. Tumor metastasis: molecular insights and evolving paradigms. Cell. 2011;147:275-292.
26. Folkman J. Role of angiogenesis in tumor growth and metastasis. Semin Oncol. 2002;29(6 suppl 16):15-18.
27. Guillerey C, SmythMJ. NKcells and cancer immunoediting [published online ahead of print May 30, 2015]. Curr Top Microbiol Immunol. 2015.
28. Labelle M, Hynes RO. The initial hours ofmetastasis: the importance of cooperative host-tumor cell interactions during hematogenous dissemination. Cancer Discov. 2012;2:1091-1099.
29. Martinelli R, Zeiger AS, Whitfield M, et al. Probing the biomechanical contribution of the endothelium to lymphocyte migration: diapedesis by the path of least resistance. J Cell Sci. 2014;127(pt 17):3720-3734.
30. Hedley BD, Chambers AF. Tumor dormancy and metastasis. Adv Cancer Res. 2009;102:67-101.
31. Gao D, Nolan D, McDonnell K, et al. Bone marrow-derived endothelial progenitor cells contribute to the angiogenic switch in tumor growth and metastatic progression. Biochim Biophys Acta. 1796;2009:33-40.
32. Jeong HS, Jones D, Liao S, et al. Investigation of the lack of angiogenesis in the formation of lymph node metastases. J Natl Cancer Inst. 2015;107.
33. O'Reilly MS, Holmgren L, Shing Y, et al. Angiostatin: a novel angiogenesis inhibitor that mediates the suppression of metastases by a Lewis lung carcinoma. Cell. 1994;79:315-328.
34. Lee YJ, Koch M, Karl D, et al. Variable inhibition of thrombospondin 1 against liver and lung metastases through differential activation of metalloproteinase ADAMTS1. Cancer Res. 2010;70:948-956.
35. Hawighorst T, Velasco P, Streit M, et al. Thrombospondin-2 plays a protective role in multistep carcinogenesis: a novel host anti-tumor defense mechanism. EMBO J. 2001;20:2631-2640.
36. Al-Mehdi AB, Tozawa K, Fisher AB, et al. Intravascular origin of metastasis fromthe proliferation of endothelium-attached tumor cells: a new model for metastasis. Nat Med. 2000;6:100-102.
37. Beije N, Jager A, Sleijfer S. Circulating tumor cell enumeration by the CellSearch system: the clinician's guide to breast cancer treatment? Cancer Treat Rev. 2015;41:144-150.
38. Okegawa T, Itaya N, Hara H, et al. Circulating tumor cells as a biomarker predictive of sensitivity to docetaxel chemotherapy in patients with castration-resistant prostate cancer. Anticancer Res. 2014;34:6705-6710.
39. Paget S. The distribution of secondary growths in cancer of the breast. Lancet. 1889;133:571-573.
40. Fidler IJ, Poste G. The "seed and soil" hypothesis revisited. Lancet Oncol. 2008;9:808.
41. Fidler IJ, Yano S, Zhang RD, et al. The seed and soil hypothesis: vascularisation and brain metastases. Lancet Oncol. 2002;3:53-57.
42. Radinsky R, Risin S, Fan D, et al. Level and function of epidermal growth factor receptor predict the metastatic potential of human colon carcinoma cells. Clin Cancer Res. 1995;1:19-31.
43. Ruoslahti E. Vascular zip codes in angiogenesis and metastasis. Biochem Soc Trans. 2004;32(pt 3):397-402.
44. Psaila B, Lyden D. The metastatic niche: adapting the foreign soil. Nat Rev Cancer. 2009;9:285-293.
45. Kang SY, Halvorsen OJ, Gravdal K, et al. Prosaposin inhibits tumor metastasis via paracrine and endocrine stimulation of stromal p53 and Tsp-1. Proc Natl Acad Sci U S A. 2009;106:12115-12120.
46. Oliver G. Lymphatic vasculature development. Nat Rev Immunol. 2004;4: 35-45.
47. Kaipainen A, Bielenberg DR. Hemangiogenesis Versus Lymphangiogenesis. Vol. 2. Oxford: Elsevier Ltd.; 2010.
48. Migliozzi MT, Mucka P, Bielenberg DR. Lymphangiogenesis and metastasis-a closer look at the neuropilin/semaphorin3 axis. Microvasc Res. 2014;96:68-76.
49. Baluk P, Fuxe J, Hashizume H, et al. Functionally specialized junctions between endothelial cells of lymphatic vessels. J Exp Med. 2007;204: 2349-2362.
50. Das S, Sarrou E, Podgrabinska S, et al. Tumor cell entry into the lymph node is controlled by CCL1 chemokine expressed by lymph node lymphatic sinuses. J Exp Med. 2013;210:1509-1528.
51. Zwaans BM, Bielenberg DR. Potential therapeutic strategies for lymphatic metastasis. Microvasc Res. 2007;74:145-158.
52. Ward PM, Weiss L. Metachronous seeding of lymph node metastases in rats bearing the MT-100-TC mammary carcinoma: the effect of elective lymph node dissection. Breast Cancer Res Treat. 1989;14: 315-320.
53. Shields JD, Emmett MS, Dunn DB, et al. Chemokine-mediated migration of melanoma cells towards lymphatics-a mechanism contributing to metastasis. Oncogene. 2007;26:2997-3005.
54. Dadras SS, Lange-Asschenfeldt B, Velasco P, et al. Tumor lymphangiogenesis predicts melanoma metastasis to sentinel lymph nodes. Mod Pathol. 2005;18:1232-1242.
55. Skobe M, Hawighorst T, Jackson DG, et al. Induction of tumor lymphangiogenesis by VEGF-C promotes breast cancer metastasis. Nat Med. 2001;7:192-198.
56. Wong SY, Haack H, Crowley D, et al. Tumor-secreted vascular endothelial growth factor-C is necessary for prostate cancer lymphangiogenesis, but lymphangiogenesis is unnecessary for lymph node metastasis. Cancer Res. 2005;65:9789-9798.
57. Weidner N, Semple JP, Welch WR, et al. Tumor angiogenesis and metastasis-correlation in invasive breast carcinoma. N Engl J Med. 1991;324:1-8.
58. Nico B, Benagiano V, Mangieri D, et al. Evaluation of microvascular density in tumors: pro and contra. Histol Histopathol. 2008;23: 601-607.
59. Uzzan B, Nicolas P, CucheratM, Perret GY.Microvessel density as a prognostic factor in women with breast cancer: a systematic review of the literature and meta-analysis. Cancer Res. 2004;64:2941-2955.
60. Kerbel R, Folkman J. Clinical translation of angiogenesis inhibitors. Nat Rev Cancer. 2002;2:727-739.
61. Eberhard A, Kahlert S, Goede V, et al. Heterogeneity of angiogenesis and blood vessel maturation in human tumors: implications for antiangiogenic tumor therapies. Cancer Res. 2000;60:1388-1393.
62. Valencak J, Heere-Ress E, Kopp T, et al. Selective immunohistochemical staining shows significant prognostic influence of lymphatic and blood vessels in patients with malignant melanoma. Eur J Cancer. 2004;40: 358-364.
63. Hlatky L, Hahnfeldt P, Folkman J. Clinical application of antiangiogenic therapy:microvessel density, what it does and doesn't tell us. J NatlCancer Inst. 2002;94:883-893.
64. Geretti E, van Meeteren LA, Shimizu A, et al. A mutated soluble neuropilin-2 B domain antagonizes vascular endothelial growth factor bioactivity and inhibits tumor progression. Mol Cancer Res. 2010;8: 1063-1073.
65. Jain RK. Normalization of tumor vasculature: an emerging concept in antiangiogenic therapy. Science. 2005;307:58-62.
66. Beecken WD, Fernandez A, Joussen AM, et al. Effect of antiangiogenic therapy on slowly growing, poorly vascularized tumors inmice.JNatlCancer Inst. 2001;93:382-387.
67. EmblemKE, Farrar CT, Gerstner ER, et al. Vessel caliber-a potentialMRI biomarker of tumour response in clinical trials. Nat Rev Clin Oncol. 2014; 11:566-584.
68. Adini A, Fainaru O, Udagawa T, et al. Matrigel cytometry: a novel method for quantifying angiogenesis in vivo. J Immunol Methods. 2009;342:78-81.
69. Iakovlev VV, Gabril M, Dubinski W, et al. Microvascular density as an independent predictor of clinical outcome in renal cell carcinoma: an automated image analysis study. Lab Invest. 2012;92:46-56.
70. Brouty-BoyéD, Zetter BR. Inhibition of cellmotility by interferon. Science. 1980;208:516-518.
71. Zhao Y, Adjei AA. Targeting angiogenesis in cancer therapy: moving beyond vascular endothelial growth factor. Oncologist. 2015;20:660-673.
72. Al-Husein B, Abdalla M, Trepte M, et al. Antiangiogenic therapy for cancer: an update. Pharmacotherapy. 2012;32:1095-1111.
73. Abdollahi A, Folkman J. Evading tumor evasion: current concepts and perspectives of anti-angiogenic cancer therapy. Drug Resist Updat. 2010;13: 16-28.
74. Folkman J. Angiogenesis inhibitors: a new class of drugs. Cancer Biol Ther. 2003;2(4 suppl 1):S127-S133.
75. Jain RK. Antiangiogenesis strategies revisited: from starving tumors to alleviating hypoxia. Cancer Cell. 2014;26:605-622.
76. Browder T, Butterfield CE, Kräling BM, et al. Antiangiogenic scheduling of chemotherapy improves efficacy against experimental drug-resistant cancer. Cancer Res. 2000;60:1878-1886.
77. Kerbel RS, Klement G, Pritchard KI, et al. Continuous low-dose antiangiogenic/ metronomic chemotherapy: from the research laboratory into the oncology clinic. Ann Oncol. 2002;13:12-15.
78. Hanahan D, Bergers G, Bergsland E. Less is more, regularly: metronomic dosing of cytotoxic drugs can target tumor angiogenesis in mice. J Clin Invest. 2000;105:1045-1047.
79. Ebos JM, Lee CR, Cruz-MunozW, et al. Accelerated metastasis after shortterm treatment with a potent inhibitor of tumor angiogenesis. Cancer Cell. 2009;15:232-239.
80. Pàez-RibesM, Allen E, Hudock J, et al. Antiangiogenic therapy elicits malignant progression of tumors to increased local invasion and distant metastasis. Cancer Cell. 2009;15:220-231.
81. Zhu XD, Sun HC, Xu HX, et al. Antiangiogenic therapy promoted metastasis of hepatocellular carcinoma by suppressing host-derived interleukin-12b in mouse models. Angiogenesis. 2013;16:809-820.